Intrathecal dexamethasone therapy for febrile infection-related epilepsy syndrome.

ABSTRACT:

Objective

Increasing reports suggest a role for immunological mechanisms in febrile infection-related epilepsy syndrome (FIRES). The objective of this study was to elucidate the efficacy and safety of intrathecal dexamethasone therapy (IT-DEX).

Methods

We assessed six pediatric patients with FIRES who were administered add-on IT-DEX in the acute (n = 5) and chronic (n = 1) phases. We evaluated clinical courses and prognosis. We measured cytokines/chemokines in cerebrospinal fluid (CSF) from FIRES patients at several points, including pre- and post-IT-DEX, and compared them with control patients with chronic epilepsy (n = 12, for cytokines/chemokines) or with noninflammatory neurological disease (NIND, n = 13, for neopterin).

Results

Anesthesia was weaned after a media

SUBMITTER: Horino A 

PROVIDER: S-EPMC7951105 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature